Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors

NCT01543698 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01543698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01543698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
May 28, 2012
Completion date
March 9, 2023
Enrollment
189 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors harboring a braf v600 mutation